Angola vs Cape Verde: Statin use vs. average non-HDL cholesterol levels
Angola
2.8
in 2018
Cape Verde
2.8
in 2018
Angola rank
163rd
Cape Verde rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Angola
- Cape Verde
How they compare
Angola currently reports 2.8 against 2.8 in Cape Verde, a difference of 0.
The two have swapped places 5 times across 39 shared years of data; in 1980 it was Angola ahead.
Angola ranks 163rd and Cape Verde ranks 163rd of 191 countries.
Angola has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Angola | Cape Verde | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.57 | 2.46 | 0.11 | Angola |
| 1990s | 2.75 | 2.67 | 0.08 | Angola |
| 2000s | 2.83 | 2.76 | 0.07 | Angola |
| 2010s | 2.84 | 2.8 | 0.0444 | Angola |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Angola or Cape Verde?
- Angola, at 2.8 against 2.8 in Cape Verde as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Angola and Cape Verde?
- 0, with Angola ahead.
- How many years of comparable data are there for Angola and Cape Verde?
- 39 years are reported by both, from 1980 to 2018.
- How do Angola and Cape Verde rank globally for statin use vs. average non-hdl cholesterol levels?
- Angola ranks 163rd and Cape Verde ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.